患有肿瘤性和非肿瘤性尿路上皮异常的患者尿液中肿瘤相关抗原（CA 19-9、组织多肽抗原和癌胚抗原）的水平

Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.

作者信息

Casetta G, Piana P, Cavallini A, Vottero M, Tizzani A

机构信息

Department of Urological Pathology, Institute of Nephro-Urology, Turin, Italy.

出版信息

Br J Urol. 1993 Jul;72(1):60-4. doi: 10.1111/j.1464-410x.1993.tb06459.x.

DOI:10.1111/j.1464-410x.1993.tb06459.x

PMID:8149183

Abstract

The urinary excretion of carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) was evaluated in 264 patients with bladder cancer. Cut-off levels were established using a pool of healthy blood donors. The combined determination of CA 19-9 and TPA had a sensitivity of 74% in pTa and 83% in pT1 tumours, and 62% in grade 1, well differentiated tumours. Absence of disease at follow-up was related to a significant decrease in CA 19-9 and TPA in 129 patients with superficial (pTa or pT1) bladder carcinoma, followed up for at least 3 years. Recurrences, defined as new tumours at the same site or elsewhere in the bladder, were associated with an increase in the mean values but this was not statistically significant. A poor prognosis was indicated in patients with infiltrating tumours and the following pre-operative levels: TPA > 1500 u/l or CA 19-9 > 300 u/ml or CEA > 50 ng/ml.

摘要

对264例膀胱癌患者的碳水化合物抗原19-9（CA 19-9）、组织多肽抗原（TPA）和癌胚抗原（CEA）的尿排泄情况进行了评估。使用一组健康献血者的样本确定了临界值。CA 19-9和TPA联合检测在pTa期肿瘤中的敏感性为74%，在pT1期肿瘤中为83%，在1级高分化肿瘤中为62%。在129例浅表性（pTa或pT1）膀胱癌患者中，随访期间无疾病复发与CA 19-9和TPA显著下降有关，这些患者至少随访了3年。复发定义为膀胱同一部位或其他部位出现新肿瘤，复发与平均值增加有关，但无统计学意义。浸润性肿瘤患者术前TPA>1500 u/l或CA 19-9>300 u/ml或CEA>50 ng/ml提示预后不良。